Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)

The optimal combination of bevacizumab with cytotoxic or cytostatic drugs in recurrent glioblastoma is unknown. We performed a phase 2 trial of combined bevacizumab and fotemustine for patients with glioblastoma at first relapse after radiotherapy and temozolomide. The primary endpoint was 6-month p...

Descripción completa

Detalles Bibliográficos
Autores principales: Soffietti, Riccardo, Trevisan, Elisa, Bertero, Luca, Cassoni, Paola, Morra, Isabella, Fabrini, Maria Grazia, Pasqualetti, Francesco, Lolli, Ivan, Castiglione, Anna, Ciccone, Giovannino, Rudà, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905193/
https://www.ncbi.nlm.nih.gov/pubmed/24293233
http://dx.doi.org/10.1007/s11060-013-1317-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905193/
https://www.ncbi.nlm.nih.gov/pubmed/24293233
http://dx.doi.org/10.1007/s11060-013-1317-x

Ejemplares similares